

REMARKS

Claims 1-7 were pending. Claims 1, 2 and 3 have been amended and claim 7 has been canceled in the present amendment. Claims 2-3 were indicated to be allowable if rewritten in independent form, and have been so amended.

Claims 1 and 4-7 were rejected under 35 U.S.C. § 112, first paragraph. The Examiner stated that, with respect to compounds having a saccharide substituent at R₁, R₂, R₃ or R₄, the specification is allegedly only enabling for compounds having glucose moiety. Applicants have hereinabove amended claim 1 to specify that the claimed compounds may be substituted with glucose or a glucose derivative. As the Examiner has acknowledged, compounds substituted with a glucose or glucose derivative at R₁ or R₂ are enabled in the specification. Applicants maintain that compounds substituted with glucose or glucose derivative at R₃ or R₄ are also enabled. The reactions set forth in the specification for substituting at R₁ or R₂ may also be used to obtain similar substitutions at R₃ or R₄. As stated on page 6, lines 19-22 of the specification, compounds substituted at R₃ or R₄ may be obtained by means of well-known processes. Thus, applicants maintain that claim 1 as amended is fully enabled by the specification.

The Examiner also stated that the specification allegedly does not enable anti-tumor treatment. Applicants respectfully traverse this ground for rejection. Applicants maintain that based on the disclosure provided in the specification, in particular the description of cytotoxicity of the claimed compounds on page 28, one skilled in the art would, without undue experimentation, be able to successfully make and use compounds of the present invention for the treatment of tumors.

In view of the present amendments and foregoing remarks, applicants maintain that the claims now pending clearly define the invention and are fully enabled by the specification.

Accordingly, applicants respectfully request reconsideration and withdrawal of the rejections set forth in the November 18, 2003 Office Action, and allowance of the pending claims.

No additional fee is required. If any fee is due, authorization is given to charge the amount of such fee to Deposit Account No. 50-0540.

Respectfully submitted,

February 18, 2004

By: W. Scott McNeas
Donald Rhoads, Reg. No. 34,705
W. Scott McNeas, Reg. No. 33,964
Attorney for Applicants
KRAMER LEVIN NAFTALIS & FRANKEL LLP
919 Third Avenue
New York, New York 10022
(212) 715-9100 (phone)
(212) 715-8000 (fax)